Call For Greater Transparency In Publishing Information From Clinical TrialsMain Category: Clinical Trials / Drug Trials
Article Date: 31 Jan 2013 - 1:00 PST
Call For Greater Transparency In Publishing Information From Clinical Trials
|Patient / Public:|
An initiative from the drugs regulator, the European Medicines Agency, to commit to releasing all of the information from clinical trials once the marketing authorization process has ended, which has been greeted with cautious optimism by proponents of access to data but with much less enthusiasm by the pharmaceutical industry, sparks an interesting debate on the role of medical journals in publishing drug data, according to the Editors of PLOS Medicine.
Writing in an Editorial, the Editors state: "As 2013 begins, it is clear that critical times lie ahead for the publishing of clinical trials, which may define the relationship between pharmaceutical companies and the public for many years to come."
The Editors argue: "It is no longer going to be the case, if it ever was, that a trial report published in a journal will be sufficient as the record of a trial - and if journals are not careful, such reports will become unnecessary as well."
The Editors continue: "So in addition to this being a critical time in the relationship of pharmaceutical companies to society in general, it seems that this is a good time to renegotiate the relationship between pharmaceutical companies and medical journals."
As data become more available for reanalysis, the Editors explain that report of a trial sanctioned by the pharmaceutical company and published in a journal will no longer be considered the definitive report of the trial. Instead, this report will become just one part of the large volume of information available around a trial, to be considered in conjunction with all analyses and data.
Over the course of 2013 as EMA defines the terms of reference for the release of data the importance of journal articles' reports of a trial will change. According to the Editors, "Some journals will find this harder to adjust to than others, especially those whose business model is heavily dependent on reprints of pharmaceutical companies' versions of trial reports."
Visit our clinical trials / drug trials section for the latest news on this subject.
Competing interests: The authors' individual competing interests are at http://www.plosmedicine.org/static/editorsInterests.action. PLOS is funded partly through manuscript publication charges, but the PLOS Medicine Editors are paid a fixed salary (their salary is not linked to the number of papers published in the journal).
Citation: The PLOS Medicine Editors (2013) Getting More Generous with the Truth: Clinical Trial Reporting in 2013 and Beyond. PLoS Med 10(1): e1001379. doi:10.1371/journal.pmed.1001379
URL PROVIDES ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001379
Public Library of Science
18 May. 2013. <http://www.medicalnewstoday.com/releases/255612.php>
Please note: If no author information is provided, the source is cited instead.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.